Roche OTC Business Review Raises Questions On Xenical Switch
This article was originally published in The Tan Sheet
Executive Summary
Roche's decision to put its nonprescription business under review may indicate that a switch of its anti-obesity drug Xenical is unlikely
You may also be interested in...
Roche Has Many Suitors For $1.4 Bil. OTC Unit
A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales
Roche Has Many Suitors For $1.4 Bil. OTC Unit
A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales
Roche Has Many Suitors For $1.4 Bil. OTC Unit
A GlaxoSmithKline/Roche consumer unit combination would have approximately $7.56 bil. in annual sales